Long survival (SV) for metastatic renal cell cancer (mRCC) after cytoreductive nephrectomy (CN) plus lung metastasectomy (LM) without targeted therapy (TT)
| Autor: | Jose F. Corona-Cruz, Miguel Angel Jimenez-Rios, Miguel Patricio Moscoso-Fernandez Salvador, Edgardo Jiménez-Fuentes, Laura Alejandra Ramírez-Tirado, Miguel Álvarez, Raúl Alejandro López Saucedo, Josue Andres Gonzalez-Luna, Oscar Gerardo Arrieta Rodriguez |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Lung biology business.industry VEGF receptors medicine.medical_treatment urologic and male genital diseases Targeted therapy medicine.anatomical_structure Internal medicine medicine biology.protein Progression-free survival Cytoreductive nephrectomy Metastasectomy business Metastatic renal cell cancer PI3K/AKT/mTOR pathway |
| Zdroj: | Journal of Clinical Oncology. 36:e16564-e16564 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | e16564Background: Reported 5-year SV for mRCC is about 10%. Introduction of inhibitors of VEGF and mTOR pathways have improved Progression Free Survival and Overall Survival (OS). High cost of new ... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|